Chemexpress(SH:688131) Zheng Quan Zhi Xing·2025-08-06 11:12Summary of Key Points Core Viewpoint - The announcement details a share reduction plan by a major shareholder of Shanghai Haoyuan Pharmaceutical Co., Ltd., indicating a need for personal funds and outlining the specifics of the planned share reduction [1][2][3]. Shareholder Holding Situation - The shareholder, Su Min Investment Junxin (Shanghai) Industry Upgrade and Technology Innovation Equity Investment Partnership (Limited Partnership), holds 6,909,364 shares, representing 3.26% of the company's total share capital prior to the reduction plan [1][2]. Reduction Plan Details - The shareholder plans to reduce holdings by up to 6,362,959 shares, which is a maximum of 3% of the total share capital. This includes a maximum of 2,120,986 shares through centralized bidding and 4,241,973 shares through block trading [1][3]. - The reduction period is set from August 29, 2025, to November 28, 2025, with the intention to execute the plan after a 15 trading day period following the announcement [1][3]. Shareholding Source - The shares to be reduced were acquired through the company's initial public offering (IPO) and subsequent capital reserve conversion, which has been publicly listed [2][3]. Compliance with Previous Commitments - The shareholder has previously committed to not transferring shares for 12 months post-IPO and will adhere to legal regulations regarding share reduction, including providing a three-day notice before any reduction [4][5][6].